At the molecular level, it decreased cardiac hypertrophy markers (ANP and BNP) and fibrotic markers (TGF-β1 and CTGF), while reducing the myocardial cell diameter and overall heart weight. The gene discussed is NPPA; the disease is cardiac hypertrophy.